Just after market close on Tuesday, specialized medical device company HeartFlow (NASDAQ: HTFL) was the very picture of health, as far as its stock was concerned. The company's shares saw a robust 14% boost in price, thanks largely to a nod from one of the world's top health regulators. The fact that this occurred on a day when the S&P 500 (SNPINDEX: ^GSPC) landed slightly in negative territory was also a plus.

HeartFlow's market-moving announcement was that the U.S. Food and Drug Administration (FDA) granted approval for its HeartFlow Plaque Analysis algorithm. Following that, the company said the product is now available for sale.

Image source: Getty Images.

Continue reading

Source Fool.com